Shares of AMN Healthcare Services, Inc. (NYSE:AHS) ended Friday session in red amid volatile trading. The shares closed down -1.38 points or -3.99% at $33.20 with 1.41 million shares getting traded. Post opening the session at $34.60, the shares hit an intraday low of $32.91 and an intraday high of $34.80 and the price vacillated in this range throughout the day. The company has a market cap of $1.54 billion and the numbers of outstanding shares have been calculated to be 48.05 million shares.
AMN Healthcare Services, Inc. (AHS) on Sept. 23, 2016 announced that its subsidiary, AMN Healthcare, Inc. (the “Company”), priced its previously announced private offering of senior notes due 2024 (the “Senior Notes”) and increased the offering size from $300 million to $325 million. The Senior Notes will bear an interest rate of 5.125% per annum and will be issued at 100.00% of their face value. The Senior Notes will be guaranteed by the Company’s affiliates that guarantee the Company’s credit facilities.
The Company intends to use the proceeds from the private offering to (i) repay (1) $138.4 million of certain existing term loan indebtedness under the Company’s credit facilities, and (2) $182.5 million under the revolving portion of its credit facilities and (ii) pay fees and expenses related to the offering.
The offering is expected to close October 3, 2016, subject to satisfaction of customary closing conditions.
Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) ended Friday session in red amid volatile trading. The shares closed down -0.73 points or -10.46% at $6.25 with 1.37 million shares getting traded. Post opening the session at $6.92, the shares hit an intraday low of $6.21 and an intraday high of $6.96 and the price vacillated in this range throughout the day. The company has a market cap of $244.83 million and the numbers of outstanding shares have been calculated to be 43.75 million shares.
Corbus Pharmaceuticals Holdings Inc (CRBP) announced that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Jefferies Cystic Fibrosis Summit on Thursday, September 29 at 1:15 p.m. ET in New York, NY.
Dr. Cohen will provide an update to its corporate progress and the clinical status and anticipated milestones for Resunab, its novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis. Resunab is currently being evaluated in three separate Phase 2 clinical studies in diffuse cutaneous systemic sclerosis (“systemic sclerosis”), cystic fibrosis (“CF”), diffuse cutaneous, and skin-predominant dermatomyositis. Corbus recently announced that it has completed subject enrollment in its Phase 2 clinical study of Resunab for the treatment of CF and the Company expects to report top-line results from this study early in the first quarter of 2017. The international, multi-center, double-blinded, randomized, placebo-control trial is supported by a $5 million development award from the Cystic Fibrosis Foundation.
A fourth NIH-sponsored clinical study of Resunab in systemic lupus erythematosus (“SLE”) is planned to begin during the first six months of 2017.